Randomized Amifostine For SCCHN

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2008

Conditions
Chemotherapeutic Agent ToxicityHead and Neck CancerMucositisRadiation ToxicityXerostomia
Interventions
DRUG

Amifostine

Given subcutaneously

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

RADIATION

radiation

Given once daily for 4 weeks and then twice daily for 2 weeks.

Trial Locations (9)

04703

Goodall Hospital, Sanford

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01742

Bethke Cancer Center at Emerson Hospital, Concord

01923

Mass General/North Shore Cancer Center, Danvers

02721

Saint Anne's Hospital - Fall River, Fall River

01854

Lowell General Hospital, Lowell

03820

Wentworth Douglass Hospital, Dover

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

MedImmune LLC

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER